Recombinant Human Endostatin Market Structure by Size, Valuable Shares, Industry Research, Top Manufacturers, Demand & Forecast Till 2026

Endostatin, a protein, is located in most Basement Membranes (BMs) in the body such as vascular basement membranes. Several research have reported the significant survival benefits of recombinant human endostatin in the treatment of late stage Non-Small-Cell Lung Carcinoma (NSCLC). In September 2005, the State Food and Drug Administration of China (CFDA) approved recombinant human endostatin (Endostar) for the treatment of NSCLC. Endostatin is expressed in various organs, with the highest levels in liver, lung, and kidney.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/recombinant-human-endostatin-market-2262

Recombinant Human Endostatin Market Drivers

Several governments are focused on reducing the cost of anticancer therapies, which is expected to boost growth of the recombinant human endostatin market during the forecast period. For instance, in August 2018, Government of China took initiatives to reduce prices of anticancer drugs by 44%. Chinese National Health and Family Planning Commission organized a national-wide drug price and reimbursement drug list negotiation, in which a total of 39 products have been successfully added including recombinant human endostatin.

Major institutes are focused on R&D in recognizing potential applications of recombinant human endostatin, which is also expected to boost growth of the market. For instance, according to a paper published in the journal Nature, September 2015, a study was conducted to evaluate effects of recombinant human endostatin in combination with radiotherapy for the treatment of esophageal squamous cell carcinoma and to discover its potential mechanisms. The findings suggested that recombinant human endostatin is a potential anti-angiogenic agent in esophageal squamous cell carcinoma mainly when combined with radiotherapy.

Furthermore, according to National Center for Biotechnology Information (NCBI) January 2017, recombinant human endostatin in combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) may aid in treatment of Angioimmunoblastic T Cell Lymphoma (AITL), a form of Peripheral T Cell Lymphoma (PTCL). Such novel therapies for PTCL treatment are immediately desired to improve the outcomes of patients with this disease. This scenario is expected to contribute to growth of the recombinant human endostatin market.

LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2262

Recombinant Human Endostatin Market Restraint

High production of recombinant human endostatin faces several challenges, which are expected to restrict the market growth. For instance, in April 2017, according to a National Center for Biotechnology Information (NCBI) report, tumor treatment needs large quantities of biologically active recombinant human endostatin, which in turn requires production of large quantities of recombinant human endostatin. This process is difficult as it based on recombinant DNA technology and also have low success rates for the treatment of cancer. Furthermore, the cost of recombinant human endostatin is high and it has short half-life. Endostatin is unstable since, endostatin-purification process may denature its structure and the resultant yields may be low.

Recombinant Human Endostatin Market – Regional Analysis

On the basis of region, the global recombinant human endostatin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global recombinant human endostatin market over the forecast period. This is owing to increasing prevalence of cancer in the U.S. For instance, according to a report by the Centers for Disease Control and Prevention (CDC), around 1,633,390 new cancer cases were reported in the U.S. in 2015 and the number is expected to reach to 1,735,350 in 2018.

The market in Asia Pacific is majorly driven by increasing number of clinical trials for recombinant human endostatin. For instance, the PLA General Hospital in China is undertaking clinical phase II study for recombinant human endostatin combination with radiotherapy for the treatment of Hepatocellular Carcinoma (HCC). The study started in January 2017 and is estimated to complete in December 2019. Moreover, Yun-fei Xia University, in China is undergoing clinical phase II study using chemotherapy and Endostar (endostatin). Endostar is administered as an intravenous infusion for the treatment of refractory nasopharyngeal carcinoma. The study started in July 2015 and is expected to complete in December 2020.

Key players operating in the global recombinant human endostatin market include, Pfizer Inc., Novus Biologicals, Biocon, Thermo Fisher Scientific, Yantai Medgenn Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., PeproTech, Inc., Onyx Pharmaceuticals, Inc., Genexine, Inc., Hetero., Intas Pharmaceuticals Ltd., and Novartis AG.

Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-sample/2262

Recombinant Human Endostatin Market – Taxonomy

By Application

• Medical Application
• Scientific Application

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.